| 前收市價 | 2.2900 |
| 開市 | 2.3400 |
| 買盤 | 1.7400 |
| 賣出價 | 2.7400 |
| 拍板 | 70.00 |
| 到期日 | 2025-01-17 |
| 今日波幅 | 2.2900 - 2.3400 |
| 合同範圍 | 無 |
| 成交量 | |
| 未平倉合約 | 54 |
- Benzinga
Merck's Keytruda Combo Therapy Less Effective Than Chemo In Lung Cancer Patients, Data Shows
https://cdn.benzinga.com/files/images/story/2023/03/17/mrk.png?optimize=medium&dpr=2&auto=webp&crop=1200%2C800 Merck & Co Inc's (NYSE: MRK) MK-7684A failed the open-label portion of a Phase 2 study KeyVibe-002 trial. MK-7684A, a combination of Keytruda (pembrolizumab) and in-house anti-TIGIT compound vibostolimab, did not improve patients' progression-free survival compared to chemotherapy in patients with metastatic non-small cell lung cancer (NSCLC) with progressive disease after treatment wit
- Insider Monkey
10 Best Psychedelic Stocks to Buy According to Hedge Funds
In this article, we discuss 10 best psychedelic stocks to buy according to hedge funds. If you want to see more stocks in this selection, check out 5 Best Psychedelic Stocks to Buy According to Hedge Funds. Data Bridge Market Research predicts that the psychedelic drugs market will expand at a compound annual growth rate […]
- Benzinga
Merck's Keytuda+Chemo Combo Improves Overall Survival In Patients With Advanced Mesothelioma
Merck & Co Inc (NYSE: MRK) announced that the Phase 2/3 CCTG IND.227/KEYNOTE-483 trial of Keytruda plus chemotherapy combo met its primary endpoint in unresectable advanced or metastatic malignant pleural mesothelioma. IND.227 was sponsored by the Canadian Cancer Trials Group (CCTG) in collaboration with investigators in Italy and France. Related: After Shelving Two Keytruda Trials, Merck Touts Encouraging Data From Keytruda Regime Study In Lung Cancer Patients. In the final analysis of the stud
